Quantifying Health Utility of Age‐related Vocal Atrophy

Julio A. de Leon,David J. Cvancara,Abbey L. Carlson,Alice Cheng,Zain H. Rizvi,J.P. Giliberto,Cara Sauder,Neel K. Bhatt
DOI: https://doi.org/10.1002/lary.31850
IF: 2.97
2024-10-28
The Laryngoscope
Abstract:Age‐related vocal atrophy (ARVA) significantly impacts quality of life (QOL). This study assessed health utility in ARVA patients using standard gamble, time trade‐off, and visual analog scale. Results highlight ARVA's severe impact on QOL, comparable to monocular blindness, emphasizing the need for further research and therapeutic development. Objective Age‐related vocal atrophy (ARVA) negatively impacts voice and quality of life (QOL). This study aims to determine utility‐based QOL in ARVA patients, correlate findings with traditional patient‐reported outcome measures (PROMs), and generate utility‐based inferences. Methods Forty ARVA patients were prospectively recruited from a tertiary care center. Health utility was measured using standard gamble, time trade‐off, and visual analog scale, assessing participants' current health states relative to defined comparison states (blindness/death). Traditional PROMs (Voice Handicap Index‐10 [VHI‐10] and Voice‐Related Quality of Life Scale [V‐RQOL]) were also collected. Descriptive and paired statistics were performed to determine health utility, and Pearson correlation assessed the association between PROMs and health utilities. Results Mean health utility in ARVA was 0.84 ± 0.22, 0.88 ± 0.17, and 0.62 ± 0.25 using standard gamble, time trade‐off, and visual analog scale, respectively. There were positive correlations between V‐RQOL and time trade‐off (r = 0.66; p
medicine, research & experimental,otorhinolaryngology
What problem does this paper attempt to address?